文献速递免疫规划

新型六价疫苗(DTaP5-IPV-HB-Hib)与五价疫苗(DTaP5-IPV-Hib)混合基础免疫程序的免疫原性与安全性

Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib).
PubMed 文献 · Vaccine · 2017-06-02

在西班牙开展的一项III期开放标签多中心研究,385名健康婴儿采用六价/五价/六价混合基础免疫程序,即2月龄和6月龄接种DTaP5-IPV-HB-Hib、4月龄接种DTaP5-IPV-Hib,并在2月龄和4月龄接种C群脑膜炎球菌结合疫苗(MCC)。混合程序第3剂后1个月,乙肝和b型流感嗜血杆菌(Hib)的应答率分别为97.2%和99.0%,其双侧95%CI下限均超过预设可接受阈值;所有受试者对白喉、破伤风和脊髓灰质炎均达到血清保护,疫苗耐受良好。

要点

  • 混合程序第3剂后1个月,乙肝应答率97.2%、Hib应答率99.0%,95%CI下限均超过预设阈值。
  • 混合程序第3剂后1个月,全部受试者对白喉、破伤风和脊髓灰质炎达到血清保护。
  • 六价疫苗与MCC疫苗混合程序同时接种未降低对疫苗抗原的免疫应答,疫苗耐受良好。

核心结论

  • 混合程序第3剂后1个月,乙肝和Hib应答率的可接受性得到证实,并观察到对所有其他六价疫苗抗原的稳健免疫应答。

研究设计与样本

  • III期、开放标签、多中心研究,在西班牙开展,共入组385名健康婴儿,384名完成研究。
  • 婴儿出生时已接种1剂乙肝疫苗,2月龄和6月龄接种DTaP5-IPV-HB-Hib(PRP-OMP结合),4月龄接种DTaP5-IPV-Hib,2月龄和4月龄接种C群脑膜炎球菌结合疫苗(MCC),并按常规接种轮状病毒和肺炎球菌疫苗。

主要发现

  • 混合程序第3剂后1个月,乙肝应答率为97.2%,Hib应答率为99.0%,两者双侧95%CI下限均大于预设可接受阈值(乙肝>90%,Hib>80%)。
  • 混合程序第3剂后1个月,全部受试者对白喉、破伤风和脊髓灰质炎达到血清保护。
  • 混合程序对所有六价疫苗抗原诱导稳健免疫应答,与MCC疫苗同时接种未降低对疫苗抗原的免疫应答。
  • 各剂次研究疫苗安全性特征良好,疫苗耐受良好。

关键数值与推荐

  • 主要目标:混合程序第3剂后1个月,乙肝应答率双侧95%CI下限>90%、Hib应答率双侧95%CI下限>80%视为可接受。
  • 次要免疫原性目标:描述混合程序完成后1个月对所有六价疫苗抗原的抗体应答,以及第2剂MCC后1个月对MCC抗原的抗体应答。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DTaP5-IPV-HB-Hib vaccine is a fully-liquid, combination hexavalent vaccine. This phase III, open-label, multicentre study conducted in Spain, evaluated the immune response to all DTaP5-IPV-HB-Hib antigens when the vaccine was used in a mixed hexa/penta/hexa primary series. Infants (who had received one dose of hepatitis B vaccine at birth) received a mixed schedule including DTaP5-IPV-HB-Hib (PRP-OMP conjugate) at 2 and 6months of age, DTaP5-IPV-Hib at 4months, meningococcal serogroup C conjugate (MCC) vaccine at 2 and 4months, and routine rotavirus and pneumococcal vaccination. One month post-dose 3 of the mixed schedule, response rates were considered acceptable if the lower bound of the two-sided 95% confidence interval around the post-vaccination response rate was >90% for hepatitis B and >80% for Haemophilus influenzae type b (Hib). Secondary immunogenicity objectives included description of the antibody response to all hexavalent antigens one month after completion of the mixed schedule, and to MCC antigen one month after the second MCC dose. The safety profile after each dose of study vaccine was described. Of 385 healthy infants enrolled, 384 completed the study. The primary objective was achieved for both hepatitis B and Hib; the lower bound of the 2-sided 95% CI of the response rates (97.2% and 99.0%, respectively) were greater than the pre-specified acceptability thresholds. One month post-dose 3 of the mixed schedule, all participants were seroprotected against diphtheria, tetanus and polio. The mixed schedule induced a robust immune response to all hexavalent antigens. The co-administration of the hexavalent vaccine in a mixed schedule with MCC vaccine did not reduce the immune response to vaccine antigens. Vaccines were well tolerated. In conclusion, the acceptability of response rates against Hib and hepatitis B were demonstrated one month post-dose 3 of the mixed schedule; robust immune responses against all other hexavalent antigens were observed. clinicaltrial.gov: NCT01839188; EudraCT: 2012-004221-25.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Martinón-Torres F, Boisnard F, Thomas S, et al. Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib). Vaccine. 2017. PMID: 28583305. doi:10.1016/j.vaccine.2017.05.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。